UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________to _________
Commission file number 001-34170
MicroVision, Inc.
|
|
|
|
6244 185th Avenue NE, Suite 100
Redmond, Washington 98052
(425) 936-6847
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
Common Stock, $0.001 par value per share |
MVIS |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES x NO ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ |
Accelerated filer x |
Non-accelerated filer ¨ |
Smaller reporting company x |
Emerging growth company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x
The number of shares of the registrant's common stock outstanding as of November 1, 2019 was 119,417,078.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION |
|
Item 1. Financial Statements (unaudited) |
Page |
Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018 |
2 |
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018 |
3 |
Condensed Consolidated Statements of Shareholders' Equity (Deficit) for the three and nine months ended September 30, 2019 and 2018 |
4 |
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018 |
5 |
Notes to Condensed Consolidated Financial Statements |
6 |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations |
15 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
20 |
Item 4. Controls and Procedures |
20 |
PART II. OTHER INFORMATION |
|
Item 1. Legal Proceedings |
21 |
Item 1A. Risk Factors |
21 |
Item 6. Exhibits |
28 |
Signatures |
29 |
1
PART I.
ITEM 1. FINANCIAL STATEMENTS
MicroVision, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except per share data)
(Unaudited)
September 30, | December 31, | |||||
2019 | 2018 | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ | 6,642 | $ | 13,766 | ||
Accounts receivable, net of allowances of $0 and $0, respectively | 505 | 476 | ||||
Costs and estimated earnings in excess of billings on uncompleted contracts | - | 987 | ||||
Inventory | 241 | 1,109 | ||||
Other current assets | 574 | 1,311 | ||||
Total current assets | 7,962 | 17,649 | ||||
Property and equipment, net | 2,111 | 2,993 | ||||
Operating lease right-of-use asset | 1,394 | - | ||||
Restricted cash | 435 | 435 | ||||
Intangible assets, net | 306 | 486 | ||||
Other assets | 186 | 1,470 | ||||
Total assets | $ | 12,394 | $ | 23,033 | ||
Liabilities and shareholders' equity (deficit) | ||||||
Current liabilities | ||||||
Accounts payable | $ | 1,091 | $ | 2,411 | ||
Accrued liabilities | 4,064 | 5,602 | ||||
Deferred revenue | 28 | - | ||||
Contract liabilities | 10,000 | - | ||||
Other current liabilities | 8 | 10,154 | ||||
Current portion of operating lease liability | 651 | - | ||||
Current portion of finance lease obligations | 24 | 21 | ||||
Total current liabilities | 15,866 | 18,188 | ||||
Operating lease liability, net of current portion | 1,482 | - | ||||
Finance lease obligations, net of current portion | 15 | 33 | ||||
Deferred rent, net of current portion | - | 695 | ||||
Total liabilities | 17,363 | 18,916 | ||||
Commitments and contingencies (Note 10) | ||||||
Shareholders' equity (deficit) | ||||||
Preferred stock, par value $0.001; 25,000 shares authorized; zero and | ||||||
zero shares issued and outstanding | - | - | ||||
Common stock, par value $0.001; 150,000 shares authorized; | ||||||
119,417 and 100,105 shares issued and outstanding at September 30, | ||||||
2019 and December 31, 2018, respectively | 119 | 100 | ||||
Additional paid-in capital | 564,227 | 550,133 | ||||
Accumulated deficit | (569,315) | (546,116) | ||||
Total shareholders' equity (deficit) | (4,969) | 4,117 | ||||
Total liabilities and shareholders' equity (deficit) | $ | 12,394 | $ | 23,033 |
The accompanying notes are an integral part of these financial statements.
2
MicroVision, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three Months Ended | Nine Months Ended | |||||||||||
September 30, | September 30, | |||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||
Product revenue | $ | 999 | $ | - | ` | $ | 1,198 | $ | - | |||
License and royalty revenue | 17 | 10,000 | 17 | 10,011 | ||||||||
Contract revenue | 174 | 1,572 | 3,066 | 5,763 | ||||||||
Total revenue | 1,190 | 11,572 | 4,281 | 15,774 | ||||||||
Cost of product revenue | 2,039 | 1,434 | 3,352 | 1,998 | ||||||||
Cost of contract revenue | 33 | 1,211 | 1,786 | 4,201 | ||||||||
Total cost of revenue | 2,072 | 2,645 | 5,138 | 6,199 | ||||||||
Gross profit | (882) | 8,927 | (857) | 9,575 | ||||||||
Research and development expense | 3,566 | 6,386 | 15,484 | 17,905 | ||||||||
Sales, marketing, general and administrative expense | 1,697 | 2,253 | 6,851 | 6,953 | ||||||||
Total operating expenses | 5,263 | 8,639 | 22,335 | 24,858 | ||||||||
Income (loss) from operations | (6,145) | 288 | (23,192) | (15,283) | ||||||||
Other income (expense), net | 4 | 1 | (7) | (19) | ||||||||
Net income (loss) | $ | (6,141) | $ | 289 | $ | (23,199) | $ | (15,302) | ||||
Net income (loss) per share - basic | $ | (0.05) | $ | 0.00 | $ | (0.21) | $ | (0.18) | ||||
Net income (loss) per share - diluted | $ | (0.05) | $ | 0.00 | $ | (0.21) | $ | (0.18) | ||||
Weighted-average shares outstanding - basic | 114,874 | 93,073 | 107,953 | 84,388 | ||||||||
Weighted-average shares outstanding - diluted | 114,874 | 93,204 | 107,953 | 84,388 |
The accompanying notes are an integral part of these financial statements.
3
MicroVision, Inc.
Condensed Consolidated Statements of Shareholders' Equity (Deficit)
(In thousands)
(Unaudited)
Common Stock | Additional | Total | ||||||||||||
Par | paid-in | Accumulated | shareholders' | |||||||||||
Shares | value | capital | deficit | equity (deficit) | ||||||||||
Balance at June 30, 2019 | 110,223 | $ | 110 | $ | 558,334 | $ | (563,174) | $ | (4,730) | |||||
Share-based compensation expense | - | - | 258 | - | 258 | |||||||||
Sales of common stock | 9,194 | 9 | 5,635 | - | 5,644 | |||||||||
Net loss | - | - | - | (6,141) | (6,141) | |||||||||
Balance at September 30, 2019 | 119,417 | $ | 119 | $ | 564,227 | $ | (569,315) | $ | (4,969) | |||||
Balance at January 1, 2019 | 100,105 | $ | 100 | $ | 550,133 | $ | (546,116) | $ | 4,117 | |||||
Share-based compensation expense | 250 | - | 877 | - | 877 | |||||||||
Sales of common stock | 19,062 | 19 | 13,217 | - | 13,236 | |||||||||
Net loss | - | - | - | (23,199) | (23,199) | |||||||||
Balance at September 30, 2019 | 119,417 | $ | 119 | $ | 564,227 | $ | (569,315) | $ | (4,969) | |||||
Balance at June 30, 2018 | 93,073 | $ | 93 | $ | 545,978 | $ | (534,457) | $ | 11,614 | |||||
Share-based compensation expense | - | - | 181 | - | 181 | |||||||||
Sales of common stock | - | - | (36) | - | (36) | |||||||||
Net income | - | - | - | 289 | 289 | |||||||||
Balance at September 30, 2018 | 93,073 | $ | 93 | $ | 546,123 | $ | (534,168) | $ | 12,048 | |||||
Balance at January 1, 2018 | 78,597 | $ | 79 | $ | 528,873 | $ | (524,086) | $ | 4,866 | |||||
Adoption of ASC 606, Revenue from Contracts with Customers | - | - | - | 5,220 | 5,220 | |||||||||
Share-based compensation expense | 76 | - | 724 | - | 724 | |||||||||
Sales of common stock | 14,400 | 14 | 16,526 | - | 16,540 | |||||||||
Net loss | - | - | - | (15,302) | (15,302) | |||||||||
Balance at September 30, 2018 | 93,073 | $ | 93 | $ | 546,123 | $ | (534,168) | $ | 12,048 |
The accompanying notes are an integral part of these financial statements.
4
MicroVision, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Nine Months Ended | ||||||
September 30, | ||||||
2019 | 2018 | |||||
Cash flows from operating activities | ||||||
Net loss | $ | (23,199) | $ | (15,302) | ||
Adjustments to reconcile net loss to net cash used in operations: | ||||||
Depreciation and amortization | 1,382 | 1,381 | ||||
Impairment of intangible assets | 97 | - | ||||
Impairment of property and equipment | 204 | - | ||||
Share-based compensation expense | 877 | 721 | ||||
Inventory write-downs | 2,203 | 1,139 | ||||
Other non-cash adjustments | - | 99 | ||||
Change in: | ||||||
Accounts receivable, net | (29) | (5,029) | ||||
Costs and estimated earnings in excess of billings on uncompleted contracts | 987 | (400) | ||||
Inventory | (1,335) | 55 | ||||
Other current and non-current assets | 2,021 | (98) | ||||
Accounts payable | (982) | (1,416) | ||||
Accrued liabilities | (1,360) | (188) | ||||
Deferred revenue | 28 | - | ||||
Billings on uncompleted contracts in excess of related costs | - | (4) | ||||
Contract liabilities and other current liabilities | (146) | (115) | ||||
Operating lease liabilities | (481) | - | ||||
Other long-term liabilities | - | (305) | ||||
Net cash used in operating activities | (19,733) | (19,462) | ||||
Cash flows from investing activities | ||||||
Purchases of property and equipment | (671) | (971) | ||||
Net cash used in investing activities | (671) | (971) | ||||
Cash flows from financing activities | ||||||
Principal payments under finance leases | (15) | (2) | ||||
Increase in deferred rent | - | 139 | ||||
Net proceeds from issuance of common stock | 13,295 | 16,540 | ||||
Net cash provided by financing activities | 13,280 | 16,677 | ||||
Change in cash, cash equivalents, and restricted cash | (7,124) | (3,756) | ||||
Cash, cash equivalents, and restricted cash at beginning of period | 14,201 | 17,401 | ||||
Cash, cash equivalents, and restricted cash at end of period | $ | 7,077 | $ | 13,645 | ||
Supplemental schedule of non-cash investing and financing activities | ||||||
Property and equipment acquired under finance leases | $ | - | $ | 42 | ||
Non-cash additions to property and equipment | 48 | 149 | ||||
Issuance of common stock for commitment fee | 258 | - | ||||
The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of | ||||||
September 30, 2019 and December 31, 2018: | ||||||
September 30, | December 31, | |||||
2019 | 2018 | |||||
Cash and cash equivalents | $ | 6,642 | $ | 13,766 | ||
Restricted cash | 435 | 435 | ||||
Cash, cash equivalents and restricted cash | $ | 7,077 | $ | 14,201 |
The accompanying notes are an integral part of these financial statements.
5
MicroVision, Inc. 1. MANAGEMENT'S STATEMENT The Condensed Consolidated Balance Sheets as of September 30, 2019, the Condensed Consolidated Statements of Operations and the Condensed Consolidated
Statements of Shareholders' Equity (Deficit) for the three and nine months ended September 30, 2019 and 2018, and the Condensed Consolidated Statements of Cash Flows for the nine months ended
September 30, 2019 and 2018, have been prepared by MicroVision, Inc. ("we" or "our") and have not been audited. In the opinion of management, all adjustments necessary to state fairly the financial
position at September 30, 2019 and the results of operations and cash flows for all periods presented have been made and consist of normal recurring adjustments. Certain information and footnote
disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules of the Securities and
Exchange Commission (SEC). The year-end condensed balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally
accepted in the United States of America. You should read these condensed consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2018. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the operating results that
may be attained for the entire fiscal year. We have incurred significant losses since inception. We have funded our operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible
debt and, to a lesser extent, from development contract revenues, product sales and licensing activities. At September 30, 2019, we had $6.6 million in cash and cash equivalents. Based on our current operating plan that includes anticipated future proceeds from the sale of shares under our
existing Purchase Agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), we anticipate that we have sufficient cash and cash equivalents to fund our operations into the first quarter of 2020.
We will require additional capital to fund our operating plan past that time. We plan to obtain additional capital through the issuance of equity or debt securities, product sales and/or licensing activities.
There can be no assurance that additional capital will be available to us or, if available, will be available on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a
timely basis,
we may consider limiting our operations substantially and we may be unable to continue as a going concern.
This limitation of operations could include reducing investments in our production capacities, research and development projects, staff, operating costs, and capital expenditures. We are introducing new technology and products into an emerging market which creates significant uncertainty about our ability to accurately project revenue, costs and cash flows. Our capital
requirements will depend on many factors, including, but not limited to, the commercial success of our laser beam scanning (LBS) engines, the rate at which original equipment manufacturers (OEMs) or
original design manufacturers (ODMs) introduce products incorporating our PicoP® scanning technology and the market acceptance and competitive position of such products. If revenues are less than
we anticipate, if the mix of revenues and the associated margins vary from anticipated amounts or if expenses exceed the amounts budgeted, we may require additional capital earlier than expected to fund
our operations. In addition, our operating plan provides for the development of strategic relationships with suppliers of components and systems and equipment manufacturers that may require additional
investments by us. These factors raise substantial doubt regarding our ability to continue as a going concern. Our unaudited consolidated financial statements have been prepared assuming we will continue as a going
concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern. 2. NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is calculated using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated using the
weighted-average number of common shares outstanding and taking into account the dilutive effect of all potential common stock equivalents outstanding. Potentially dilutive common stock equivalents
primarily consist of options, warrants and nonvested restricted stock units (RSUs). Net loss per share for the three months ended September 30, 2019 and the nine months ended September 30, 2019 and
2018, assuming dilution, is equal to basic net loss per share because the effect of dilutive securities outstanding during the period, including options and RSUs computed using the treasury stock method, is
anti-dilutive. Basic net income per share for the three months ended September 30, 2018 is diluted by the potentially dilutive outstanding securities per the table below. 6
The components of basic and diluted net income (loss) per share were as follows (in thousands, except per share data): For the three and nine months ended September 30, 2019, we excluded the following securities from net income (loss) per share as the effect of including them would have been anti-dilutive: options
outstanding exercisable into a total of 5,206,000 shares of common stock and 1,247,000 nonvested RSUs. For the three and nine months ended September 30, 2018, we excluded the following securities
from net income (loss) per share as the effect of including them would have been anti-dilutive: options outstanding and warrants exercisable into a total of 7,586,000 and 7,587,000 shares of common stock,
respectively, and 1,050,000 and 1,180,000 nonvested RSUs, respectively. 3. LONG-TERM CONTRACTS In May 2018, we signed a five-year license agreement with a customer granting them exclusive license to our LBS technology for display-only applications. As part of the agreement, we received a
first payment of $5.0 million in June 2018 and the second payment of $5.0 million in October 2018. The contract includes requirements that must be met in order to maintain exclusivity. If this licensee
acquires a customer, the agreement requires the licensee to buy any needed components from us. During the year ended December 31, 2018 we completed the performance obligations required by the
contract. As a result, we recognized $10.0 million in license and royalty revenue during the year ended December 31, 2018. In April 2017, we signed a contract with a major technology company to develop an LBS display system. Under the agreement, we received an upfront payment of $10.0 million in 2017 and, as of
September 30, 2019, have also received $15.0 million, net of early payment discounts, representing all payment due for development work. The original contract was for $14.0 million in fees for
development work, but we and our customer agreed to add $1.1 million in additional work to total $15.1 million. After applying early payment discounts, we recognized revenue of $15.0 million in
development fees over time based on the proportion of total cost expended (under Topic 606, the "input method") to the total cost expected to complete the contract performance obligation. For
the three and nine months ended September 30, 2019, we recognized $47,000 and $2.9 million, respectively, of contract revenue from development fees on this agreement compared to $1.5 million and
$5.6 million, respectively, during the three and nine months ended September 30, 2018. The $10.0 million upfront payment will be recognized as revenue at the point in time future component sales are transferred to the customer. Based on current pricing and cost estimates, the amount of
the per unit upfront payment would be greater than our estimated per unit gross profit. We have an amount equal to the $10.0 million upfront payment classified as a contract liability on the balance sheet.
We have received initial purchase orders from our customer under the product supply agreement signed in April 2017. We expect to apply $877,000 of the upfront payment over the two quarters ended
December 31, 2019 and March 31, 2020. To the extent that the component purchases do not fully expend the $10.0 million upfront payment, there is no repayment provision to the customer. 7
4. REVENUE RECOGNITION The following is a description of principal activities from which we generate revenue. Revenues are recognized when control of the promised goods or services are transferred to our customers, in
an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We generate all of our revenue from contracts with customers. We evaluate contracts based on the 5-step model as stated in Topic 606 as follows: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the
transaction price, and (v) recognize revenue when (or as) performance obligations are satisfied. A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue
standard. The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to
determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of
variable consideration will require a significant amount of judgment. In estimating the transaction price we will use either the expected value method or the most likely amount method. The transaction price is allocated to the separate performance obligations in the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging
when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable.
Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on our part. Revenue is recognized when (or as) the customer obtains control of the good or service/performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation
is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time. Disaggregation of revenue The following table provides information about disaggregated revenue by timing of revenue recognition, (in thousands): 8
Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands): Under Topic 606, our rights to consideration are presented separately depending on whether those rights are conditional or unconditional. We present our unconditional rights to consideration as
"accounts receivable" in our Consolidated Balance Sheet. Contract assets represent rights to consideration that are subject to a condition other than the passage of time and will be comprised primarily of costs and estimated profits in excess of billings on
uncompleted contracts and estimated accrued sales-based royalty revenue. Contract costs in excess of billing are included in the "Costs and estimated earnings in excess of billings on uncompleted contracts" line of our Consolidated Balance Sheet. 9
Significant changes in the contract assets and the contract liabilities balances during the period are as follows (in thousands, except percentages): During the nine months ended September 30, 2019, we billed $3.9 million on our development contract. Of this amount, $987,000 was
included in contract assets at December 31, 2018. We also recognized revenue of $2.9 million on development contract during the nine months ended September 30, 2019. Contract acquisition costs We are required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed. We currently do not pay any commissions upon the signing
of a contract; therefore, no commission cost has been incurred as of September 30, 2019. Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting
period. The $10.0 million upfront payment received from a major technology company will be recognized as revenue at the point in time future component sales are transferred to the customer. We have
received initial purchase orders from our customer under the product supply agreement signed in April 2017. We expect to apply $877,000 of the $10.0 million contract liability over the two quarters
ended December 31, 2019 and March 31, 2020 and this amount is included in revenue below. Because there is uncertainty about the timing of the application of the remainder of the $10.0 million
contract liability, it has been excluded from future estimated revenue in the table below.
The $10.0 million contract liability is classified as a current liability on our balance sheet. Due to the uncertainty of the timing, it is possible that recognition of revenue may extend beyond the next
twelve months. The following table provides information about the estimated timing of revenue recognition (in thousands): 5. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS AND SUPPLIERS Concentration of credit risk Financial instruments that potentially subject us to a concentration of credit risk are primarily cash equivalents and accounts receivable. We typically do not require collateral from our customers.
As of September 30, 2019, our cash and cash equivalents are comprised of short-term highly rated money market savings accounts. Concentration of major customers and suppliers 10
A significant concentration of our components and the products we sell are currently manufactured and obtained from single or limited-source suppliers. The loss of any single or limited-source supplier,
the failure of any of these suppliers to perform as expected, or the disruption in the supply chain of components from these suppliers could subject us to risks and uncertainties including, but not limited to,
increased cost of sales, possible loss of revenues, or significant delays in product deliveries, any of which could adversely affect our financial condition and operating results. 6. INVENTORY Inventory consists of the following: Inventory consists of raw materials and finished goods assemblies. Inventory is computed using the first-in, first-out (FIFO) method and is stated at the lower of cost and net realizable value.
Management periodically assesses the need to account for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required. During the three and nine months
ended September 30, 2019, we recorded $1.4 million and $2.2 million, respectively, in inventory write-downs. As of September 30, 2019 and December 31, 2018, $168,000 and $1.4 million, respectively, of
materials that are not expected to be consumed during the next twelve months are classified as "other assets" on the balance sheet. 7. SEVERANCE ARRANGEMENTS In the nine months ended September 2019, we completed the development work under the April 2017 contract, therefore, to better align our resources to support our business needs, we reduced
our workforce by approximately 27%. In the three months ended June 30, 2019, we recorded expenses related to severance of approximately $300,000 to research and development expense and
approximately $90,000 to sales, marketing, and general and administrative expense. We paid $284,000 during the three months ended September 30, 2019 related to the severance agreements for these
employees. We plan to make the remaining severance payments during the fourth quarter of 2019. 8. SHARE-BASED COMPENSATION We issue share-based compensation to employees in the form of stock options, RSUs, and performance stock units (PSUs). We account for the share-based awards by recognizing the fair value of
share-based compensation expense on a straight-line basis over the service period of the award, net of estimated forfeitures. The fair value of stock options is estimated on the grant date using the Black-Scholes
option pricing model. The fair value of RSUs is determined by the closing price of our common stock on the grant date. The PSUs are valued using a binomial option pricing model using the
following inputs: stock price, volatility, and risk-free interest rates. Changes in estimated inputs or using other option valuation methods may result in materially different option values and share-based
compensation expense. The following table summarizes the amount of share-based compensation expense by line item on the statements of operations: 11
Options activity and positions The following table summarizes shares, weighted-average exercise price, weighted-average remaining contractual term and aggregate intrinsic value of options outstanding and options exercisable
as of September 30, 2019: During the nine months ended September 30, 2019 we issued 475,000 stock options and 195,000 PSUs to our executive officers. These PSUs have performance vesting criteria that would require the
Company's stock price to appreciate by more than 100% of the stock price on the grant date before they become earned. Earned PSUs are eligible to vest as to one-third of the PSUs subject to the
Award on each of the first three anniversaries of May 22, 2019, subject to the recipient's employment on the above vesting dates. PSUs that become earned prior to a vesting date that would have
vested on any earlier vesting date would become immediately vested. As of September 30, 2019, our unrecognized share-based employee compensation related to stock options was $1.4 million which we plan to amortize over the next 2.2 years, our unrecognized share-based
compensation related to RSUs was $394,000 which we plan to amortize over the next 1.6 years, and our unrecognized share-based compensation related to the PSUs was $17,000, which we plan to
amortize over the next 2.0 years. 9. LEASES In February 2016, the FASB issued Accounting Standards Update 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use (ROU) asset and lease
liability in the balance sheet for all leases, including operating leases, with terms of more than twelve months. Recognition, measurement and presentation of expenses and cash flows from a lease by a
lessee have not significantly changed from previous guidance. The amendments also require qualitative disclosures along with specific quantitative disclosures. We adopted this guidance using the
cumulative-effect adjustment method on January 1, 2019, meaning we did not restate prior periods. Current year financial information is presented under the guidance in Topic
842, while prior year information will continue to be presented under Topic 840. Adoption of the standard resulted in the recognition of an operating ROU asset of approximately $1.6 million, a lease
liability of approximately $2.5 million, and a reduction in other short-term and long-term liabilities of $873,000. Adoption of the standard did not have a material impact on our Statement of Operations or
Statement of Cash flows. Accounting for our finance leases remains substantially unchanged. We determine if an arrangement is a lease at inception. On our balance sheet, our office lease is included in Operating lease right-of-use asset, Current portion of operating lease liability and Operating
lease liability, net of current portion. On our balance sheet, finance leases are included in Property and equipment, Current portion of finance lease obligations and Finance lease obligations, net of current
portion. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets
and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. For leases that do not provide an implicit rate, we use our incremental borrowing
rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Lease expense for lease payments
is recognized on a straight-line basis over the lease term. Significant judgment may be required when determining whether a contract contains a lease, the length of the lease term, the allocation of the consideration in a contract between lease and non-lease
components, and the determination of the discount rate included in our office lease. We review the underlying objective of each contract, the terms of the contract, and consider our current and future
business conditions when making these judgments. 12
Our leases have remaining lease terms of two to four years. Our office space lease contains an option to extend the lease for one period of five years. This extension period is not included in our ROU
asset or lease liability amounts. Our office lease agreement includes both lease and non-lease components, which are accounted for separately. Our finance leases contain options to purchase the leased
property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless we are reasonably certain to exercise the purchase option. The components of lease expense were as follows: Supplemental cash flow information related to leases was as follows: 13
Supplemental balance sheet information related to leases was as follows: As of September 30, 2019, maturities of lease liabilities were as follows: 10. COMMITMENTS AND CONTINGENCIES Litigation In March 2019, we filed a Notice of Arbitration in Hong Kong against Ragentek as a result of its failure to perform its obligations under a purchase order with us.
The relief sought is $4.0 million dollars plus interest and arbitration costs. At this time we cannot predict the likelihood of a favorable outcome. We are subject to various claims and pending or threatened lawsuits in the normal course of business. We are not currently party to any legal proceedings that management believes are reasonably
possible to have a material adverse effect on our financial position, results of operations or cash flows. 14
Purchase commitments At September 30, 2019, we had $2.6 million in open purchase obligations that represent commitments to purchase inventory, materials, capital equipment, and other goods used in the normal
operation of our business. 11. COMMON STOCK AND WARRANTS In July 2019, we raised $2.0 million before issuance costs of approximately $24,000 through a registered direct offering of 3.0 million shares of our common stock to a
private investor. In April 2019, we raised $2.0 million before issuance costs of approximately $34,000 through a registered direct offering of 2.3 million shares of our common stock to a private investor. In April 2019, we entered into a Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC (Lincoln Park) granting us the right to sell shares of our common stock having an aggregate
value of up to $11.0 million. Under the terms of the agreement, Lincoln Park made an initial purchase of $1.0 million in shares of common stock at a purchase price of $0.98 per share. Subject to various
limitations and conditions set forth in the agreement, we may sell up to an additional $10.0 million in shares of common stock, from time to time, at our sole discretion to Lincoln Park over a 24-month period
beginning April 2019. In consideration for entering into the agreement, we issued 250,000 shares of our common stock, having a value of $258,000, based on the closing stock price at the date of grant, to
Lincoln Park as a commitment fee. We incurred an additional $92,000 in issuance costs. As of September 30, 2019, we have issued 11.8 million shares and raised a total of $8.3 million under this
agreement. In January 2019, we raised $1.2 million before issuance costs of approximately $26,000 through a registered direct offering of 2.0 million shares of our common stock to a private investor. In December 2018, we raised $4.2 million before issuance costs of approximately $524,000 through an underwritten public offering of 7.0 million shares of our common stock. In June 2018, we raised $18.0 million before issuance costs of approximately $1.4 million through an underwritten public offering of 14.4 million shares of our common stock. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Forward-looking statements The information set forth in this report in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations," and Item 3, "Quantitative and Qualitative Disclosures
about Market Risk," includes "Forward-Looking Statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), and is subject to the safe harbor created by those sections. Such statements may include, but are not limited to, projections of revenues, income or loss,
capital expenditures, plans for product development and cooperative arrangements, technology development by third parties, future operations, financing needs or plans of MicroVision, Inc.
("we," "our," or "us"), as well as assumptions relating to the foregoing. The words "anticipate," "could," "would," "believe," "estimate," "expect," "goal," "may," "plan,"
"project," "will," and similar expressions identify forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include risk
factors identified below in Item 1A. Overview MicroVision, Inc. is a pioneer in laser beam scanning (LBS) technology that we market under our brand name PicoP®. We have developed our proprietary scanning technology that can be used
in products for interactive projection, consumer light detection and ranging (LiDAR), automotive LiDAR, and augmented and mixed reality. Our PicoP® scanning technology is based on our patented
expertise in systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, and electronics and how those elements are packaged into a small form factor, low power
scanning engine that can display, interact and sense, depending on the needs of the application. These systems utilize edge computing and machine intelligence as part of the solutions. 15
Our strategy includes selling LBS engines to original equipment manufacturers (OEMs) and original design manufacturers (ODMs). We plan to offer scanning engines to support a wide array of
applications: an interactive scanning engine for smart home speakers and other Internet of Things (IoT) products, a LiDAR engine for consumer electronic applications, and solutions for augmented and
mixed reality devices. We also are developing LiDAR for automotive collision avoidance systems. In addition to selling engines, we have licensed our patented PicoP® scanning technology to other companies for incorporation into their scanning engines for projection. We sell our customers key
components needed to produce their laser scanning engines and/or license our technology in exchange for a royalty fee or margin for each scanning engine they sell. Companies to whom we license our
PicoP® scanning technology are typically OEMs or ODMs who are in the business of making components or products ready for sale to end users. To date, we have primarily focused on the consumer
electronics market, however, we believe that our LBS technology could support multiple applications and markets including automotive, medical, and industrial. While we are optimistic about our technology and the potential for future revenues, we have incurred substantial losses since inception and we expect to incur a significant loss during the fiscal year
ending December 31, 2019. Key accounting policies and estimates Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that materially affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent liabilities. We evaluate our estimates on a continuous basis. We base our estimates on historical data, terms of existing contracts, our
evaluation of trends in the consumer display and 3D sensing industries, information provided by our current and prospective customers and strategic partners, information available from other outside
sources and on various other assumptions we believe to be reasonable under the circumstances. The results form the basis for making judgments regarding the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Except for policy changes in accounting for leases associated with our
adoption of Topic 842 (see Note 9 "Leases" in the Notes to Condensed Consolidated Financial Statements in Item 1), there have been no significant changes to our critical accounting judgments,
policies, and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2018. Results of operations Product revenue Product revenue is revenue from sales of our products which are LBS engines, MEMS and ASICs. Revenue is recognized when control of the goods passes to the customer. Our quarterly product
revenue may vary substantially due to the timing of product orders from customers, product shipments, production constraints and availability of components and raw materials. The increase in product revenue for the three and nine months ended September 30, 2019 compared to 2018 was primarily due to product shipments to a major technology company and includes
$360,000 related to selling display engines produced for Ragentek, and previously written off, to another customer. Product revenue backlog at September 30, 2019 and 2018 was $5.5 million and $3.2 million, respectively. The September 30, 2019 backlog is primarily due to the initial production orders received from
a major technology company under the product supply agreement signed in April 2017. Because there is uncertainty about the timing of the revenue recognition of the $10.0 million contract liability, it has
been excluded from product revenue backlog at September 30, 2019. The backlog at September 30, 2018 was primarily an order from Ragentek. Ragentek failed to meet their obligations under the March
2017 order. We are pursuing our legal rights to enforce the contract. 16
License and royalty revenue License and royalty revenue is revenue under license agreements to our PicoP® scanning technology. We recognize revenue on upfront license fees at a point in time if the nature of the license
granted is a right-to-use license, representing functional intellectual property with significant standalone functionality. If the nature of the license granted is a right-to-access license, representing symbolic
intellectual property, which excludes significant standalone functionality, we recognize revenue over the period of time we have ongoing obligations under the agreement. We will recognize sales-based
royalties based on information received by our customers. If such information is not received, we will estimate the number of royalty-bearing products consumed by our customers each quarter. In May 2018, we signed a five-year license agreement with a customer granting them exclusive license to our LBS technology for display-only applications. The license represents functional intellectual
property which derives a substantial portion of its utility from its significant standalone functionality. The intellectual property is not expected to substantially change during the license period, nor are we
contractually or practically required to use updated intellectual property during the license life. During the three months ended September 30, 2018 we completed the performance obligations required by
the contract. As a result, we recognized all of the $10.0 million of up-front license payments in license revenue for the three and nine months ended September 30, 2018. Contract revenue Contract revenue includes revenue from performance on development contracts and the sale of prototype units and evaluation kits based on our PicoP® scanning engine. Our contract revenue in a
particular period is dependent upon when we enter into a contract, the value of the contracts we have entered into, and the availability of technical resources to perform work on the contracts. We recognize
contract revenue either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable(s) occur over time, the revenue is recognized in proportion to
the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized at the completion of the contract. In contracts that include significant customer
acceptance provisions, we recognize revenue only upon acceptance of the deliverable(s). In April 2017, we signed a contract with a major technology company to develop an LBS display system. As of September 30, 2019, we have received all payments due for development work. We
have recognized revenue of $15.0 million in development fees, net of early payment discounts, over time utilizing the input method of total costs expended to total cost expected to complete the performance
obligation. The original contract was for $14.0 million in fees for development, but we and the customer agreed to add $1.1 million in additional work to total $15.1 million. The decrease in contract revenue during the three and nine months ended September 30, 2019 compared to the same period in 2018 was attributed to decreased contract activity. Our contract backlog,
including orders for prototype units and evaluation kits, at September 30, 2019 and 2018 was approximately zero and $4.2 million, respectively. Cost of product revenue 17
Cost of product revenue includes the direct and allocated indirect costs of products sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs
incurred directly, or charged to us by our contract manufacturers, in the manufacture of these products. Indirect costs include labor, manufacturing overhead, and other costs associated with operating our
manufacturing capabilities and capacity. Manufacturing overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of product revenue based
on the proportion of indirect labor which supported production activities.
Cost of product revenue can fluctuate significantly from period to period, depending on the product mix and volume, the level of manufacturing overhead expense and the volume of direct material
purchased. The increase during the three and nine months ended September 30, 2019 compared to the same period in 2018 was attributed to $1.4 million and $2.2 million, respectively, of inventory write-downs,
and to a lesser extent, product shipments to a major technology company. Cost of product revenue excludes costs related to revenue recognized under the Ragentek contract because the inventory related
to that contract was previously written down. Cost of contract revenue Cost of contract revenue includes both the direct and allocated indirect costs of performing on contracts and producing prototype units and evaluation kits. Direct costs include labor, materials and other
costs incurred directly in producing prototype units and evaluation kits or performing on a contract. Indirect costs include labor and other costs associated with operating our research and development
department and building our technical capabilities and capacity. Cost of contract revenue is determined by the level of direct and indirect costs incurred, which can fluctuate substantially from period to
period. The decrease in the cost of contract revenue during the three and nine months ended September 30, 2019 compared to the same period in 2018
was primarily attributed to reduced activity on the April 2017 development contract. Research and development expense Research and development expense consists of compensation related costs of employees and contractors engaged in internal research and product development activities, direct material to support
development programs, laboratory operations, outsourced development and processing work, and other operating expenses. We assign our research and development resources based on the business
opportunity of the available projects, the skill mix of the resources available and the contractual commitments we have made to our customers. We believe that a substantial level of continuing research and
development expense will be required to further develop our scanning technology. The decrease in research and development expense during the three months ended September 30, 2019 compared to the same period in 2018 was attributable to lower subcontractor costs, headcount
and personnel-related compensation and benefits, and direct material costs. The decrease in research and development expense during the nine months ended September 30, 2019 compared to the same
period in 2018 was attributable to lower subcontractor costs offset by higher allocation of resources to internal research and development activities that were previously allocated to a commercial contract
and higher direct materials costs related to our LBS engine development. 18
Sales, marketing, general and administrative expense Sales, marketing, general and administrative expense includes compensation and support costs for marketing, sales, management and administrative staff, and for other general and administrative
costs, including legal and accounting services, consultants and other operating expenses. The decrease in sales, marketing, general and administrative expense during the three months ended September 30, 2019 compared to the same period in 2018 was attributed to lower personnel-related
compensation and benefits expenses and lower professional and outside services costs. Liquidity and capital resources We have incurred significant losses since inception. We have funded operations to date primarily through the sale of common stock, convertible preferred stock, warrants,
the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales, and licensing activities. At September 30, 2019, we had $6.6 million in cash and cash
equivalents. Based on our current operating plan that includes anticipated future proceeds from the sale of shares under our existing Purchase Agreement with Lincoln Park, we
anticipate that we have sufficient cash and cash equivalents to fund our operations into the first quarter of 2020. We will require additional capital to fund our operating plan past that time. We plan to
obtain additional capital through the issuance of equity or debt securities, product sales and/or licensing activities. There can be no assurance that additional capital will be available to us or, if available, will
be available on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis,
we may consider limiting our operations substantially and we may be unable to continue as a going concern.
This limitation of operations could include reducing investments in our production capacities, research and development projects, staff, operating costs, and capital expenditures. Under the April 2017 development contract, we received an upfront payment of $10.0 million in 2017 with a major technology company. The $10.0 million upfront payment will be applied as a
upfront payment toward future component purchases from us. Based on current pricing and cost estimates, the amount of per unit upfront payment would be greater than our estimated per unit gross profit and
therefore will have a negative impact on our reported cash flow from operating activities until the upfront payment has been earned. These factors raise substantial doubt regarding our ability to continue as a going concern. Our unaudited consolidated financial statements have been prepared assuming we will continue as a going
concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern. Operating activities Cash used in operating activities totaled $19.7 million during the nine months ended September 30, 2019 compared to cash used in operating activities of $19.5 million during the same period in
2018. The significant changes in operating activities were primarily attributed to the timing of payments received from customers and payments made to suppliers during the nine months ended September
30, 2019 compared to the same period in 2018. Investing activities During the nine months ended September 30, 2019 and 2018, net cash used in investing activities was $671,000 and $971,000, respectively, and was primarily attributed to purchases of property
and equipment. 19
Financing activities In July 2019, we raised $2.0 million before issuance costs of approximately $24,000 through a registered direct offering of 3.0 million shares of our common stock to a private investor. In April 2019, we raised $2.0 million before issuance costs of approximately $34,000 through a registered direct offering of 2.3 million shares of our common stock to a private investor. In April 2019, we entered into a Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC (Lincoln Park) granting us the right to sell shares of our common stock having an aggregate
value of up to $11.0 million. Under the terms of the agreement, Lincoln Park made an initial purchase of $1.0 million in shares of common stock at a purchase price of $0.98 per share. Subject to various
limitations and conditions set forth in the agreement, we may sell up to an additional $10.0 million in shares of common stock, from time to time, at our sole discretion to Lincoln Park over a 24-month period
beginning April 2019. In consideration for entering into the agreement, we issued 250,000 shares of our common stock, having a value of $258,000, based on the closing stock price at the date of grant, to
Lincoln Park as a commitment fee. We incurred an additional $92,000 in issuance costs. As of September 30, 2019, we have issued 11.8 million shares and raised a total of $8.3 million under this
agreement. In January 2019, we raised $1.2 million before issuance costs of approximately $26,000 through a registered direct offering of 2.0 million shares of our common stock to a private investor. In December 2018, we raised $4.2 million before issuance costs of approximately $524,000 through an underwritten public offering of 7.0 million shares of our common stock. In June 2018, we raised $18.0 million before issuance costs of approximately $1.4 million through an underwritten public offering of 14.4 million shares of our common stock. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Interest rate and market liquidity risk As of September 30, 2019, all of our cash and cash equivalents have variable interest rates. Therefore, we believe our exposure to market and interest rate risk is not material. Our investment policy generally directs that the investment manager should select investments to achieve the following goals: principal preservation, adequate liquidity and return. As of September 30,
2019, we had $6.6 million in cash and cash equivalents, which are comprised of operating checking accounts and short-term, highly rated money market savings accounts. Foreign exchange rate risk Our major contract and collaborative research and development agreements, product sales, and licensing activity payments are currently made in U.S. dollars. However, in the future we may enter
into contracts or collaborative research and development agreements in foreign currencies that may subject us to foreign exchange rate risk. We have entered into purchase orders and supply agreements
in foreign currencies in the past and may enter into such arrangements, from time to time, in the future. We believe our exposure to currency fluctuations related to these arrangements is not material. We
may enter into foreign currency hedges to offset material exposure to currency fluctuations when we can adequately determine the timing and amounts of the exposure. ITEM 4. CONTROLS AND PROCEDURES Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report and, based on this evaluation, our Principal
Executive Officer and Principal Financial Officer have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting (as
defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934) that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting. 20
PART II. In March 2019, we filed a Notice of Arbitration in Hong Kong against Ragentek as a result of its failure to perform its obligations under a purchase order with us. The relief sought is $4.0
million dollars plus interest and arbitration costs. At this time we cannot predict the likelihood of a favorable outcome. We are also subject to various claims and pending or threatened lawsuits in the normal course of business. We are not currently party to any other legal proceedings that management believes are
reasonably possible to have a material adverse effect on our consolidated financial position, results of operations or cash flows. You should carefully consider the risks described below together with the other information set forth in this report, which could materially affect our business, financial condition and future results.
The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our
business, financial condition and operating results. Risk Factors Related to Our Business and Industry We have a history of operating losses and expect to incur significant losses in the future. We have had substantial losses since our inception. We cannot assure you that we will ever become or remain profitable. The likelihood of our success must be considered in light of the expenses, difficulties and delays frequently encountered by companies formed to develop and commercialize new technologies. In
particular, our operations to date have focused primarily on research and development of our PicoP® scanning technology system and development of demonstration units. We are unable to accurately
estimate future revenues and operating expenses based upon historical performance. We cannot be certain that we will succeed in obtaining additional development revenue or commercializing our technology or products. In light of these factors, we expect to continue to incur significant
losses and negative cash flow at least through 2019 and likely thereafter. We cannot be certain that we will achieve positive cash flow at any time in the future. We will require additional capital to fund our operations and to implement our business plan. If we do not obtain additional capital, we may be required to curtail
our operations substantially. Raising additional capital may dilute the value of current shareholders' shares. Based on our current operating plan that includes anticipated future proceeds from the sale of shares under our existing Purchase Agreement with Lincoln Park, we anticipate
that we have sufficient cash and cash equivalents to fund our operations into the first quarter of 2020. We will require additional capital to fund our operating plan past that time. We plan to obtain
additional capital through the issuance of equity or debt securities, product sales and/or licensing activities. We are introducing new technology and products into an emerging market which creates significant uncertainty about our ability to accurately project revenue, costs and cash flows. Our capital
requirements will depend on many factors, including, but not limited to, the commercial success of our LBS engines, the rate at which OEMs and ODMs introduce products incorporating our PicoP®
scanning technology and the market acceptance and competitive position of such products. If revenues are less than we anticipate, if the mix of revenues and the associated margins varies from anticipated
amounts or if expenses exceed the amounts budgeted, we may require additional capital earlier than expected to fund our operations. In addition, our operating plan provides for the development of
strategic relationships with suppliers of components, products and systems, and equipment manufacturers that may require additional investments by us. 21
Additional capital may not be available to us or, if available, may not be available on terms acceptable to us or on a timely basis. Raising additional capital may involve issuing securities with rights and
preferences that are senior to our common stock and may dilute the value of our current shareholders' shares. If adequate capital resources are not available on a timely basis, we may consider limiting our
operations substantially and we may be unable to continue as a going concern. This limitation of operations could include reducing investments in our production capacities or research and development
projects, staff, operating costs, and capital expenditures which could jeopardize our ability to achieve our business goals or satisfy our customer requirements. Qualifying a new or alternative contract manufacturer or foundry for our products could cause us to experience delays that result in lost revenues and damaged customer relationships. We rely on single or limited-source suppliers to manufacture our products. Establishing a relationship with a new or alternative contract manufacturer(s) or foundry is a time-consuming process, as our
unique technology may require significant manufacturing process adaptation to achieve full manufacturing capacity. Accordingly, we may be unable to establish a relationship with new or alternative contract
manufacturers in the short-term, or at all, at prices or on other terms that are acceptable to us. Changes in our supply chain may result in increased cost and delay and may subject us to risks and uncertainties regarding, but not limited to, product warranty, product liability and quality control
standards. The loss of any single or limited-source supplier, the failure of any of these suppliers to perform as expected or the disruption in the supply chain of components from these suppliers could cause
significant delays in product deliveries, which may result in lost revenues and damaged customer relationships. To the extent that we are not able to establish a relationship with a new or alternative contract
manufacturer(s) or foundry in a timely manner, we may be unable to meet contract or production milestones, which could have a material adverse effect on our financial condition, results of operations and
cash flows. Our success will depend, in part, on our ability to secure significant third party manufacturing resources. Our success will depend, in part, on our ability to provide our components and future products in commercial quantities at competitive prices and on schedule. Accordingly, we will be required to obtain
access, through business partners or contract manufacturers, to manufacturing capacity and processes for the commercial production of our expected future products. Our foreign contract manufacturers could experience severe financial difficulties or other disruptions in their business, and such continued supply could be significantly reduced or terminated. In
addition, we cannot be certain that we will successfully obtain access to needed manufacturing resources concurrent with a significant increase in our planned production levels. Future manufacturing
limitations of our suppliers could constrain the number of products that we are able to develop and produce. We are dependent on third parties in order to develop, manufacture, sell and market products incorporating our PicoP® scanning technology, scanning engines, and the scanning engine
components. Our business strategy for commercializing our technology in products incorporating PicoP® scanning technology includes entering into development, manufacturing, licensing, sales and marketing
arrangements with OEMs, ODMs and other third parties. These arrangements reduce our level of control over production and distribution and may subject us to risks and uncertainties regarding, but not
limited to, product warranty, product liability and quality control standards. We cannot be certain that we will be able to negotiate arrangements on acceptable terms, if at all, or that these arrangements will be successful in yielding commercially viable products. If we cannot
establish these arrangements, we would require additional capital to undertake such activities on our own and would require extensive manufacturing, sales and marketing expertise that we do not currently
possess and that may be difficult to obtain. In addition, we could encounter significant delays in introducing our PicoP® scanning technology or find that the development, manufacture or sale of products incorporating our technology would not
be feasible. To the extent that we enter into development, manufacturing, licensing, sales and marketing or other arrangements, our revenues will depend upon the performance of third parties. We cannot
be certain that any such arrangements will be successful. 22
We cannot be certain that our technology system or products incorporating our PicoP® scanning technology will achieve market acceptance. If our technology system or products incorporating our
technology do not achieve market acceptance, our revenues may not grow. Our success will depend in part on customer acceptance of our PicoP® scanning technology. Our technology may not be accepted by manufacturers who use display and 3D sensing technologies
in their products, by systems integrators, OEMs, and ODMs who incorporate the scanning engine components into their products or by end users of these products. To be accepted, our PicoP®
scanning technology must meet the expectations of our current and potential customers in the consumer electronics, automotive, and other markets. If our technology system or products incorporating our
PicoP® scanning technology do not achieve market acceptance, we may not be able to continue to develop our technology. Future products incorporating our PicoP® scanning technology and scanning engines are dependent on advances in technology by other companies. Our PicoP® scanning technology will continue to rely on technologies, such as laser diode light sources and other components that are developed and produced by other companies. The
commercial success of certain future products incorporating our PicoP® scanning technology will depend, in part, on advances in these and other technologies by other companies. We may, from time
to time, contract with and support companies developing key technologies in order to accelerate the development of them for our or our customers' specific uses. There are no guarantees that such activities
will result in useful technologies or products that will be profitable. We are dependent on a small number of customers for our revenue. Our quarterly performance may vary substantially and this variance, as well as general market conditions, may cause our stock
price to fluctuate greatly and potentially expose us to litigation. For the nine months ended September 30, 2019, one customer accounted for $3.7 million in revenue, representing 86% of our total revenue. A second customer accounted for $559,000 in revenue,
representing 13% of our total revenue. For the nine months ended September 30, 2018, one customer accounted for $10.0 million in revenue, representing 63% of our total revenue. A second customer
accounted for $5.6 million in revenue, representing 35% of our total revenue. Our customers take time to obtain, and the loss of a significant customer could negatively affect our revenue. Our quarterly
operating results may vary significantly based upon: In one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors and the trading price of our common stock may decline as a consequence. In
addition, following periods of volatility in the market price of a company's securities, shareholders often have instituted securities class action litigation against that company. If we become involved in a class action suit, it could divert the attention of management and, if adversely determined, could require us to pay substantial damages. We or our customers may fail to perform under open orders or agreements, which could adversely affect our operating results and cash flows. Our backlog under open orders and agreements totaled $5.5 million as of September 30, 2019. We or our customers may be unable to meet the performance requirements and obligations under open
orders or agreements, including performance specifications, milestones or delivery dates, required by such purchase orders or agreements. Furthermore, our customers may be unable or unwilling to
perform their obligations thereunder on a timely basis, or at all if, among other reasons, our products and technologies do not achieve market acceptance, our customers' products and technologies do not
achieve market acceptance or our customers otherwise fail to achieve their operating goals. To the extent we are unable to perform under such purchase orders or agreements or to the extent customers
are unable or unwilling to perform, our operating results and cash flows could be adversely affected. 23
We may not be able to maintain our listing on The Nasdaq Global Market and it may become more difficult to sell our stock in the public market. Our common stock is listed on The Nasdaq Global Market. To maintain our listing on this market, we must meet Nasdaq's listing maintenance standards. If we are unable to continue to
meet Nasdaq's listing maintenance standards for any reason, our common stock could be delisted from The Nasdaq Global Market. On June 13, 2019, we received a deficiency notice from The Nasdaq Stock Market advising us that for 30
consecutive business days preceding the date of the notice, the bid price of our common stock had closed below the
$1.00 per share minimum required for continued listing on The Nasdaq Global Market. In accordance with Nasdaq's
listing rules, we have 180 calendar days, or until December 10, 2019, to regain compliance with this requirement. We can
regain compliance with the minimum closing bid price rule if the bid price of our common stock closes at $1.00 or
higher for a minimum of ten consecutive business days during this 180-day compliance period. From the date
of the deficiency notice to the date of filing of this Quarterly Report on Form 10-Q, the bid price of our common stock
has not closed at $1.00 or higher. If compliance is not achieved by December 10, 2019, Nasdaq will provide written
notification to us that our securities are subject to delisting. If our common stock does not trade at a level that is likely to regain compliance with Nasdaq's listing rules, our Board of Directors will consider
the options available to achieve compliance, including effecting a reverse stock split if necessary. If our common stock were delisted, we may seek to list our common stock on a regional stock exchange, or, if one or more broker-dealer market makers comply with applicable requirements, the
over-the-counter (OTC) market. Listing on such other market or exchange could reduce the liquidity of our common stock. If our common stock were to trade in the OTC market, an investor would find it more
difficult to dispose of, or to obtain accurate quotations for the price of, the common stock. A delisting from The Nasdaq Global Market could also subject our common stock to so-called penny stock rules that impose additional sales practice and market-making requirements on broker-dealers
who sell or make a market in such securities. Consequently, removal from The Nasdaq Global Market and failure to obtain listing on another market or exchange could affect the ability or willingness of
broker-dealers to sell or make a market in our common stock and the ability of purchasers of our common stock to sell their securities in the secondary market. On November 1, 2019, the closing price of our common stock was $0.74 per share. Our lack of financial and technical resources relative to our competitors may limit our revenues, potential profits, overall market share or value. Our products and potential products incorporating our PicoP® scanning technology will compete with established manufacturers of existing products and companies developing new technologies.
Many of our competitors have substantially greater financial, technical and other resources than we have. Because of their greater resources, our competitors may develop products or technologies that
may be superior to our own. The introduction of superior competing products or technologies could result in reduced revenues, lower margins or loss of market share, any of which could reduce the value of
our business. We may not be able to keep up with rapid technological change and our financial results may suffer. The consumer display and 3D sensing industries have been characterized by rapidly changing technology, accelerated product obsolescence and continuously evolving industry standards. Our success
will depend upon our ability to further develop our PicoP® scanning technology system and to cost effectively introduce new products and features in a timely manner to meet evolving customer
requirements and compete with competitors' product advances. We may not succeed in these efforts due to: The occurrence of any of the above factors could result in decreased revenues, market share and value of our business. 24
We could face lawsuits related to our use of PicoP® scanning technology or other technologies. Defending these suits would be costly and time-consuming. An adverse outcome, in any such
matter, could limit our ability to commercialize our technology or products incorporating our PicoP® scanning technology, reduce our revenues and increase our operating expenses. We are aware of several patents held by third parties that relate to certain aspects of light scanning displays and 3D sensing products. These patents could be used as a basis to challenge the validity,
limit the scope or limit our ability to obtain additional or broader patent rights of our patents or patents we have licensed. A successful challenge to the validity of our patents or patents we have licensed
could limit our ability to commercialize our technology or products incorporating our PicoP® scanning technology and, consequently, materially reduce our revenues. Moreover, we cannot be certain that
patent holders or other third parties will not claim infringement by us with respect to current and future technology. Because U.S. patent applications are held and examined in secrecy, it is also possible that
presently pending U.S. applications will eventually be issued with claims that will be infringed by our products or our technology. The defense and prosecution of a patent suit would be costly and time-consuming, even if the outcome were ultimately favorable to us. An adverse outcome in the defense of a patent suit could subject
us to significant costs, require others and us to cease selling products incorporating our technology, require us to cease licensing our technology or require disputed rights to be licensed from third parties.
Such licenses, if available, would increase our operating expenses. Moreover, if claims of infringement are asserted against our future co-development partners or customers, those partners or customers
may seek indemnification from us for any damages or expenses they incur. If we fail to manage expansion effectively, our revenue and expenses could be adversely affected. Our ability to successfully offer products incorporating PicoP® scanning technology and implement our business plan in a rapidly evolving market requires an effective planning and management
process. The growth in business and relationships with customers and other third parties has placed, and will continue to place, a significant strain on our management systems and resources. We will
need to continue to improve our financial and managerial controls, reporting systems and procedures, and will need to continue to train and manage our work force. If we fail to adequately reduce and control our manufacturing, supply chain and operating costs, our business, financial condition, and operating results could be adversely affected. We incur significant costs related to procuring components and increasing our production capabilities to manufacture our products. We may experience delays, cost overruns or other unexpected costs
associated with an increase in production. If we are unsuccessful in our efforts to reduce and control our manufacturing, supply chain and operating costs and keep costs aligned with the levels of revenues
we generate, our business and financial condition could suffer. Our technology and products incorporating our PicoP® scanning technology may be subject to future environmental, health and safety regulations that could increase our development and
production costs. Our technology and products incorporating our PicoP® scanning technology could become subject to future environmental, health and safety regulations or amendments that could negatively impact
our ability to commercialize our technology and products incorporating our PicoP® scanning technology. Compliance with any such new regulations would likely increase the cost to develop and
produce products incorporating our PicoP® scanning technology, and violations may result in fines, penalties or suspension of production. If we become subject to any environmental, health, or safety
laws or regulations that require us to cease or significantly change our operations to comply, our business, financial condition and operating results could be adversely affected. Our operating results may be adversely impacted by worldwide political and economic uncertainties and specific conditions in the markets we address. In the recent past, general worldwide economic conditions have experienced a downturn due to slower economic activity, concerns about inflation, increased energy costs, decreased consumer
confidence, reduced corporate profits and capital spending, and adverse business conditions. Any continuation or worsening of the current global economic and financial conditions could materially
adversely affect: (i) our ability to raise, or the cost of, needed capital, (ii) demand for our current and future products, and (iii) our ability to commercialize products. We cannot predict the timing, strength, or
duration of any economic slowdown or subsequent economic recovery, worldwide, regionally or in the display industry. 25
Because we plan to continue using foreign contract manufacturers, our operating results could be harmed by economic, political, regulatory and other factors in foreign countries. We currently use foreign contract manufacturers and plan to continue to use foreign contract manufacturers to manufacture current and future products, where appropriate. These international
operations are subject to inherent risks, which may adversely affect us, including, but not limited to: Our contract manufacturers' facilities could be damaged or disrupted by a natural disaster or labor strike, either of which would materially affect our financial position, results of operations and cash
flows. A major catastrophe, such as an earthquake, monsoon, flood or other natural disaster, labor strike, or work stoppage at our contract manufacturers' facilities, our suppliers, or our customers, could result
in a prolonged interruption of our business. A disruption resulting from any one of these events could cause significant delays in product shipments and the loss of sales and customers, which could have a
material adverse effect on our financial condition, results of operations, and cash flows. Intellectual property protection for our products, processes and technology is important and uncertain. If we do not obtain effective intellectual property protection for our products, processes and
technology, we may be subject to increased competition. Our commercial success will depend, in part, on our ability to maintain the proprietary nature of our PicoP® scanning technology and other key
technologies by securing valid and enforceable patents and effectively maintaining unpatented technology as trade secrets. We protect our proprietary PicoP® scanning technology by seeking to obtain United States and foreign patents in our name, or licenses to third party patents, related to proprietary technology,
inventions, and improvements that may be important to the development of our business. However, our patent position involves complex legal and factual questions. The standards that the United States
Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Additionally, the scope of patents is subject to interpretation by courts and their validity can be subject to challenges and defenses, including challenges and defenses based on the existence of prior art.
Consequently, we cannot be certain as to the extent to which we will be able to obtain patents for our new products and technology or the extent to which the patents that we already own, protect our
products and technology. Reduction in scope of protection or invalidation of our licensed or owned patents, or our inability to obtain new patents, may enable other companies to develop products that
compete directly with ours on the basis of the same or similar technology. We also rely on the law of trade secrets to protect unpatented know-how and technology to maintain our competitive position. We try to protect this know-how and technology by limiting access to the
trade secrets to those of our employees, contractors and partners, with a need-to-know such information and by entering into confidentiality agreements with parties that have access to it, such as our
employees, consultants and business partners. Any of these parties could breach the agreements and disclose our trade secrets or confidential information, or our competitors might learn of the information
in some other way. If any trade secret not protected by a patent were to be disclosed to or independently developed by a competitor, our competitive position could be negatively affected. We could be subject to significant product liability claims that could be time-consuming and costly, divert management attention and adversely affect our ability to obtain and maintain insurance
coverage. We could be subject to product liability claims if any of the product applications are alleged to be defective or cause harmful effects. For example, because some of the scanning engines incorporating
our PicoP® scanning technology could scan a low power beam of colored light into the user's eye, the testing, manufacture, marketing and sale of these products involve an inherent risk that product
liability claims will be asserted against us. 26
Additionally, any misuse of our technology or products incorporating our PicoP® scanning technology by end users or third parties that obtain access to our technology, could result in negative
publicity and could harm our brand and reputation. Product liability claims or other claims related to our products or our technology, regardless of their outcome, could require us to spend significant time
and money in litigation, divert management time and attention, require us to pay significant damages, harm our reputation or hinder acceptance of our products. Any successful product liability claim may
prevent us from obtaining adequate product liability insurance in the future on commercially desirable or reasonable terms. An inability to obtain sufficient insurance coverage at an acceptable cost or
otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our products and our PicoP® scanning technology. Our contracts and collaborative research and development agreements have long sales cycles, which makes it difficult to plan our expenses and forecast our revenues. Our contracts and collaborative research and development agreements have long sales cycles that involve numerous steps including determining the product application, exploring the technical
feasibility of a proposed product, evaluating the costs of manufacturing a product or qualifying a new or alternative contract manufacturer for production. Our long sales cycle, which can last several years,
makes it difficult to predict the quarter in which revenue recognition will occur. Delays in entering into contracts and collaborative research and development agreements could cause significant variability in
our revenues and operating results for any particular period. Our contracts and collaborative research and development agreements may not lead to any product or any products that will be profitable. Our contracts and collaborative research and development agreements, including without limitation, those discussed in this document, are exploratory in nature and are intended to develop new types of
products for new applications. Our efforts may prove unsuccessful and these relationships may not result in the development of any product or any products that will be profitable. Our operations could be adversely impacted by information technology system failures, network disruptions, or cyber security breaches. We rely on information technology systems to process, transmit, store, and protect electronic data between our employees, our customers and our suppliers. Our systems are vulnerable to damage or
interruptions due to events beyond our control, including, but are not limited to, natural disasters, power loss, telecommunications failures, computer viruses, hacking, or other cyber security issues. Our
system redundancy may be inadequate and our disaster recovery planning may be ineffective or insufficient to account for all eventualities. Additionally, we maintain insurance coverage to address certain
aspects of cyber risks. Such insurance coverage may be insufficient to cover all losses or all claims that may arise, should such an event occur. Loss of any of our key personnel could have a negative effect on the operation of our business. Our success depends on our executive officers and other key personnel and on the ability to attract and retain qualified new personnel. Achievement of our business objectives will require
substantial additional expertise in the areas of sales and marketing, research and product development and manufacturing. Competition for qualified personnel in these fields is intense, and the inability to
attract and retain additional highly skilled personnel, or the loss of key personnel, could hinder our ability to compete effectively in the LBS markets and adversely affect our business strategy execution and
results of operations. 27
Exhibit Description 10.1 31.1 31.2 32.1 32.2 101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
(1) Incorporated by reference to the Company's Current Report on Form 8-K filed on July 23, 2019. 28
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. MICROVISION, INC. Date: November 6, 2019 By: /s/ Perry M. Mulligan Perry M. Mulligan Chief Executive Officer and Director Date: November 6, 2019 By: /s/ Stephen P. Holt Stephen P. Holt Chief Financial Officer 29
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
2019
2018
2019
2018
Numerator:
Net income (loss) available for common shareholders - basic
$
(6,141)
$
289
$
(23,199)
$
(15,302)
Denominator:
Weighted-average common shares outstanding - basic
114,874
93,073
107,953
84,388
Dilutive incremental share effect from:
Options
-
1
-
-
Nonvested restricted stock units
-
130
-
-
Weighted-average common shares outstanding - diluted
114,874
93,204
107,953
84,388
Net income (loss) per share - basic
$
(0.05)
$
0.00
$
(0.21)
$
(0.18)
Net income (loss) per share - diluted
$
(0.05)
$
0.00
$
(0.21)
$
(0.18)
Three Months Ended September 30, 2019
License and
Product
royalty
Contract
revenue
revenue
revenue
Total
Timing of revenue recognition:
Products transferred at a point in time
$
999
$
17
$
121
$
1,137
Product and services transferred over time
-
-
53
53
Total
$
999
$
17
$
174
$
1,190
Nine Months Ended September 30, 2019
License and
Product
royalty
Contract
revenue
revenue
revenue
Total
Timing of revenue recognition:
Products transferred at a point in time
$
1,198
$
17
$
173
$
1,388
Product and services transferred over time
-
-
2,893
2,893
Total
$
1,198
$
17
$
3,066
$
4,281
Three Months Ended September 30, 2018
License and
Product
royalty
Contract
revenue
revenue
revenue
Total
Timing of revenue recognition:
Products transferred at a point in time
$
-
$
10,000
$
26
$
10,026
Product and services transferred over time
-
-
1,546
1,546
Total
$
-
$
10,000
$
1,572
$
11,572
Nine Months Ended September 30, 2018
License and
Product
royalty
Contract
revenue
revenue
revenue
Total
Timing of revenue recognition:
Products transferred at a point in time
$
-
$
10,011
$
182
$
10,193
Product and services transferred over time
-
-
5,581
5,581
Total
$
-
$
10,011
$
5,763
$
15,774
September 30,
December 31,
2019
2018
Accounts receivable, net
$
505
$
476
Costs and estimated earnings in excess of billings on uncompleted contracts
-
987
Deferred revenue
28
-
Contract liabilities
10,000
-
Other current liabilities
-
10,000
September 30,
December 31,
2019
2018
$ Change
% Change
Contract assets
$
-
$
987
$
(987)
(100.0)
Contract liabilities
(10,028)
-
(10,028)
-
Net contract assets (liabilities)
$
(10,028)
$
987
$
(11,015)
(1,116.0)
Remainder of 2019
2020
Product revenue
$
3,482
$
2,796
License and royalty revenue
84
57
Contract revenue
9
19
September 30,
December 31,
(in thousands)
2019
2018
Raw materials
$
-
$
32
Finished goods
241
1,077
$
241
$
1,109
Share-based compensation expense
Three Months Ended
Nine Months Ended
September 30,
September 30,
(in thousands)
2019
2018
2019
2018
Cost of product revenue
$
25
$
-
$
26
$
-
Research and development expense
84
109
283
377
Sales, marketing, general and administrative expense
149
73
568
344
$
258
$
182
$
877
$
721
Weighted-
Weighted-
Average
Average
Remaining
Aggregate
Exercise
Contractual
Intrinsic
Options
Shares
Price
Term (years)
Value
Outstanding as of September 30, 2019
5,206,000
$
1.65
7.7
$
-
Exercisable as of September 30, 2019
2,315,000
$
2.46
5.9
$
-
Three Months Ended
Nine Months Ended
September 30,
September 30,
(in thousands)
2019
2019
Operating lease expense
$
116
$
348
Finance lease expense:
Amortization of leased assets
4
12
Interest on lease liabilities
2
5
Total finance lease expense
6
17
Total lease expense
$
122
$
365
Three Months Ended
Nine Months Ended
September 30,
September 30,
(in thousands)
2019
2019
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows from operating leases
$
160
$
481
Operating cash flows from finance leases
2
5
Financing cash flows from finance leases
6
15
Right-of-use assets obtained in exchange for new lease obligations:
Operating leases
$
-
$
1,638
Finance leases
-
-
(in thousands)
September 30, 2019
Operating leases
Operating lease right-of-use assets
$
1,394
Current portion of operating lease liability
651
Operating lease liability, net of current portion
1,482
Total operating lease liabilities
$
2,133
Finance leases
Property and equipment, at cost
$
66
Accumulated depreciation
(21)
Property and equipment, net
$
45
Current portion of finance lease obligations
$
24
Finance lease obligations, net of current portion
15
Total finance lease liabilities
$
39
Weighted Average Remaining Lease Term
Operating leases
4 years
Finance leases
2 years
Weighted Average Discount Rate
Operating leases
6.0%
Finance leases
13.8%
Operating
Finance
(in thousands)
leases
leases
2019
$
160
$
7
2020
656
27
2021
676
9
2022
696
-
2023
175
-
Thereafter
-
-
Total minimum lease payments
2,363
43
Less: amount representing interest
(230)
(4)
Present value of lease liabilities
$
2,133
$
39
(in thousands)
2019
2018
$ change
% change
Three Months Ended September 30,
$
999
$
-
$
999
-
Nine Months Ended September 30,
1,198
-
1,198
-
(in thousands)
2019
2018
$ change
% change
Three Months Ended September 30,
$
17
$
10,000
$
(9,983)
(99.8)
Nine Months Ended September 30,
17
10,011
(9,994)
(99.8)
(in thousands)
2019
2018
$ change
% change
Three Months Ended September 30,
$
174
$
1,572
$
(1,398)
(88.9)
Nine Months Ended September 30,
3,066
5,763
(2,697)
(46.8)
% of
% of
product
product
(in thousands)
2019
revenue
2018
revenue
$ change
% change
Three Months Ended September 30,
$
2,039
204.1
$
1,434
-
$
605
42.2
Nine Months Ended September 30,
3,352
279.8
1,998
-
1,354
67.8
% of
% of
contract
contract
(in thousands)
2019
revenue
2018
revenue
$ change
% change
Three Months Ended September 30,
$
33
19.0
$
1,211
77.0
$
(1,178)
(97.3)
Nine Months Ended September 30,
1,786
58.3
4,201
72.9
(2,415)
(57.5)
(in thousands)
2019
2018
$ change
% change
Three Months Ended September 30,
$
3,566
$
6,386
$
(2,820)
(44.2)
Nine Months Ended September 30,
15,484
17,905
(2,421)
(13.5)
(in thousands)
2019
2018
$ change
% change
Three Months Ended September 30,
$
1,697
$
2,253
$
(556)
(24.7)
Nine Months Ended September 30,
6,851
6,953
(102)
(1.5)
Number
(Principal Executive Officer)
(Principal Financial Officer and Principal Accounting Officer)